SCHEMBL2867647

SCHEMBL2867647

Cn1c(C(c2ccccc2)C2CCCCC2)nc2ccccc21

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.55
KDM4E B2RXH2 2/20 0.55
TP53 P04637 1/20 0.50
KMT2A Q03164 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.44
TSHR P16473 1/20 0.44
MEN1 O00255 1/20 0.44
CYP2D6 P10635 1/20 0.43
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM5 P08912 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
TAAR1 Q96RJ0 1/20 0.42
MAPK1 P28482 1/20 0.42
ALDH1A1 P00352 1/20 0.41
LCK P06239 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
ALOX5 P09917 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716234 0.81 KMT2A (0.51) LMNAKDM4ETP53KMT2ASMN1; SMN2
SCHEMBL717350 0.81 TP53 (0.56) LMNAKDM4ETP53KMT2ASMN1; SMN2
SCHEMBL1520483 0.76 SMN1; SMN2 (0.58) LMNAKDM4ETP53KMT2ASMN1; SMN2
SCHEMBL2678538 0.72 LMNA (0.60) LMNAKDM4EKMT2ASMN1; SMN2TSHR
SCHEMBL1691699 0.72 LMNA (0.60) LMNAKDM4EKMT2ASMN1; SMN2TSHR
SCHEMBL1248051 0.72 IDO1 (0.57) LMNAKMT2AMEN1CHRM2CHRM4
SCHEMBL718402 0.71 RCE1 (0.49) LMNAKDM4ETP53KMT2ASMN1; SMN2
SCHEMBL15455572 0.70 ERCC1 (0.43) LMNACHRM2CHRM4CHRM5CHRM1
SCHEMBL6650399 0.70 GAA (0.55) LMNAKMT2AMEN1CHRM2CHRM4
SCHEMBL11697197 0.70 TDP1 (0.67) LMNAKDM4ETP53KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2253328-A1 Cycloalkyl inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-11-24 EP disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed
US-20050234106-A1 Cycloalkyl inhibitors of potassium channel function LLOYD JOHN 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234106-A1 Cycloalkyl inhibitors of potassium channel function KCNJ2, KCNN3, KCNQ5 LMNA 1535/4885KDM4E 820/4885TP53 4680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.